Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer (Q45287928)
Jump to navigation
Jump to search
scientific article published on 28 February 2005
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer |
scientific article published on 28 February 2005 |
Statements
1 reference
Significantly higher pathologic complete remission rate after neoadjuvant therapy with trastuzumab, paclitaxel, and epirubicin chemotherapy: results of a randomized trial in human epidermal growth factor receptor 2-positive operable breast cancer (English)
1 reference
Kelly K Hunt
1 reference
Gabriel N Hortobagyi
1 reference
Sonja E Singletary
1 reference
Aman U Buzdar
1 reference
Nuhad K Ibrahim
1 reference
Deborah Francis
1 reference
Daniel J Booser
1 reference
Eva S Thomas
1 reference
Richard L Theriault
1 reference
Lajos Pusztai
1 reference
Marjorie C Green
1 reference
Banu K Arun
1 reference
Massimo Cristofanilli
1 reference
Debra K Frye
1 reference
Terry L Smith
1 reference
Aysegul A Sahin
1 reference
Michael S Ewer
1 reference
Thomas A Buchholz
1 reference
Donald Berry
1 reference
28 February 2005
1 reference
1 reference
23
1 reference
16
1 reference
3676-3685
1 reference
Identifiers
1 reference
1 reference